CS-7017

DRUG7 trials

Sponsors

Daiichi Sankyo, Daiichi Sankyo Co., Ltd.

Conditions

Advanced CancerAdvanced Non-small Cell Lung Cancer (NSCLC)Anaplastic Thyroid CancerCarcinoma, Non-Small-Cell LungColorectal CancerNeoplasm

Phase 1

Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer

CompletedNCT00408434

Daiichi SankyoNeoplasm

Start: 2006-11-30End: 2010-02-28Updated: 2020-10-19

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

TerminatedNCT00603941

Daiichi SankyoAnaplastic Thyroid Cancer

Start: 2008-01-31End: 2011-12-31Updated: 2020-09-16

Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017

CompletedNCT00881569

Daiichi SankyoAdvanced Cancer

Start: 2009-03-31End: 2011-09-30Updated: 2020-09-28

CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

CompletedNCT01199068

Daiichi Sankyo Co., Ltd.Carcinoma, Non-Small-Cell Lung

Start: 2010-06-30End: 2011-12-31Updated: 2021-05-13

CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

CompletedNCT01199055

Daiichi Sankyo Co., Ltd.Carcinoma, Non-Small-Cell Lung

Start: 2010-03-31End: 2011-07-31Updated: 2020-07-07

Phase 2

Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy

TerminatedNCT00986440

Daiichi SankyoColorectal Cancer

Start: 2009-07-31End: 2012-10-29Updated: 2020-11-05

Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

CompletedNCT01101334

Daiichi SankyoAdvanced Non-small Cell Lung Cancer (NSCLC)

Start: 2010-03-31End: 2013-04-30Updated: 2020-06-16